At present, the new drugs for the treatment of ulcerative colitis in China are mainly biological agents and microecological agents. 1. Biological agents: immune factors are considered to be important factors leading to ulcerative colitis, and biological agents targeting cytokines are emerging therapeutic drugs for the treatment of the disease, such as adalimumab, infliximab, vedolizumab, etc. 2. Microecological agents: intestinal flora imbalance is also one of the participants in the etiology of ulcerative colitis, microecological agents can correct the imbalance of intestinal microflora, such as Lactobacillus acidophilus, Bifidobacterium bifidum, etc., which need to be further verified in the clinic. Drugs for the treatment of this disease need more clinical validation to be promoted, patients need to be based on specific conditions under the guidance of a doctor to use drugs, not blindly self-medication.